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Brief RepOrt
Background: In an effort to evaluate the single agent activity of 
temsirolimus in previously untreated non–small-cell lung cancer, the 
North Central Cancer Treatment Group undertook a frontline “win-
dow-of-opportunity” study.
Methods: Patients received 25 mg of temsirolimus administered 
intravenously as a weekly 30 minute infusion, on a 4-week cycle. 
Based on a two-stage Fleming design, the treatment would be prom-
ising if at least four of the first 25 evaluable patients in stage I or 
at least six of the 50 evaluable patients at the end of stage II have a 
confirmed response. Fresh tumor biopsies were obtained to evaluate 
predictive markers of temsirolimus activity.
Results: A total of 55 patients were enrolled with 52 patients being 
evaluable. The median age was 64 years. Adverse events (grade 3/4) 
occurring in 33 patients included dyspnea (12%), fatigue (10%), 
hyperglycemia (8%), hypoxia (8%), nausea (8%), and rash/desqua-
mation (6%). The clinical benefit rate was 35% with four patients 
achieving a confirmed partial response and 14 patients with stable 
disease for 8 weeks or more. The 24-week progression-free survival 
rate was 25%. Median progression-free survival and overall survival 
were 2.3 and 6.6 months, respectively. Expression of p70s6 kinase, 
phospho-p70s6 kinase, Akt, phospho-Akt, and phosphatase and 
tensin homolog mutation did not correlate with clinical outcome.
Conclusions: Temsirolimus given as a single agent in frontline therapy 
in patients with non–small-cell lung cancer was tolerable and demon-
strated clinical benefit but did not meet the primary objective in this 
study. Patient selection will be needed to enhance the efficacy.
Key Words: mToR inhibitors, Advanced non–small-cell lung carci-
noma, Temsirolimus, Window of opportunity.
(J Thorac Oncol. 2012;7: 919–922)
The prognosis of advanced non–small-cell lung cancer (NSCLC) patients treated with platinum-doublet regimens 
remains poor with a median progression-free survival (PFS) 
of 3.1 to 5.5 months and a median overall survival (oS) of 
7. to -11.3 months.1 Advances in maintenance chemotherapy 
still yield a median oS of 12 to 15 months with pemetrexed 
or erlotinib.2,3 Thus, novel therapies are required to improve 
treatment outcomes.
The phosphoinositide 3–kinase/Akt/mammalian target 
of rapamycin (mToR) pathway is one of the key signaling path-
ways in cancer. It plays roles in cell growth, cell proliferation, 
angiogenesis, and protein synthesis. It is also dysregulated in 
many human cancers including NSCLC.4 Phosphorylation of 
mToR, in response to the activation of a growth receptor by its 
ligand, leads to the modulation of two different pathways: the 
eukaryotic initiation factor 4E binding protein-1 and the 40S 
ribosomal protein S6 kinase (p70s6k).5 The tumor suppressor 
gene phosphatase and tensin homolog (PTEN), is a negative 
regulator of the pathway. Loss or inactivating mutations of 
this gene result in gain of function of the phosphoinositide- 
3-kinase, catalytic, alpha polypeptide gene itself and the con-
stitutively active mutant forms of receptor tyrosine kinases 
or the Ras oncogene, which occur frequently in NSCLC.4 
The mToR inhibitors such as temsirolimus, everolimus, 
and deforolimus are being evaluated in cancer clinical trials. 
Everolimus and temsirolimus have been approved for the ther-
apy of renal cell carcinoma.6,7
It had been assumed that the efficacy of novel agents in 
NSCLC will be more accurately determined if these agents 
were tested in the frontline setting because of the emergence 
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of resistance arising from exposure to various therapies over 
time. on the basis of this assumption, a frontline “window-
of-opportunity” study was designed. Patients with previ-
ously untreated NSCLC received single-agent temsirolimus, 
and were closely monitored. Standard platinum-based che-
motherapy was introduced at the first sign of progression. 
Furthermore, putative predictive markers of temsirolimus 
activity (p70S6k, Akt, and PTEN) were evaluated.
METHODS
Chemotherapy naïve patients with histologic or cyto-
logic evidence of measurable metastatic NSCLC were eligible 
for this study. other eligibility criteria were standard for phase 
II studies (see Supplementary Content, http://links.lww.com/
JTo/A274).
Temsirolimus at a dose of 25 mg dissolved in 250 ml of 
0.9% saline was administered intravenously over 30 minutes 
every week (4 week-cycle length) until progression, unac-
ceptable toxicity, patient refusal, or investigator’s decision to 
remove patients from the study.
Biomarkers of temsirolimus effect were evaluated in 
tumor biopsy samples obtained from 13 patients at base-
line. Thirteen usable tumor biopsy samples were obtained. 
Immunohistochemistry was performed for p70s6 kinase, 
Phospho-p70s6 kinase, Akt, phospho-Akt, and PTEN expres-
sion. PTEN mutation was also evaluated by direct sequencing. 
Immunohistochemistry was graded as previously described 
and the staining index was calculated as staining intensity (0–3 
scale) multiplied by percentage of tumor cells stained (see 
Supplementary Content, http://links.lww.com/JTo/A274).8
A two-stage single arm Phase II study based on a 
Fleming design9 was used to assess the primary endpoint of 
confirmed response rate (CRR), which is complete response 
and partial response (PR) by Response Evaluation Criteria in 
Solid Tumors10 in patients with metastatic NSCLC to temsi-
rolimus on two consecutive evaluations at least more than 4 
weeks apart. The treatment would be considered promising if 
at least four of the first 25 evaluable patients have a CRR or at 
least six of the 50 evaluable patients at the end of study have 
a CRR. If only one success out of 25 patients is observed at 
the end of stage I, the treatment regimen would be considered 
ineffective and the study would be terminated. However, in 
the event that only 2 or 3 successes were observed in stage I, 
the study would proceed to stage II. This design with a sample 
size of 50 evaluable patients had an exact significance level of 
0.05 and 94% power to detect an effective treatment given that 
the true CRR is at least 20%.
The secondary endpoints included the 24-week PFS 
rate, oS, clinical benefit rate (confirmed response and con-
firmed stable disease [SD; lasting 8 weeks or more from the 
time of first SD assessment]), and evaluation of predictive 
markers of activity of temsirolimus.
RESULTS
Patient and Treatment Characteristics
A total of 55 patients (52 evaluable) were enrolled 
between February 27, 2004 and November 3, 2006. one 
patient died before study initiation and 2 were deemed ineli-
gible. Baseline characteristics for the 52 patients are summa-
rized in Table 1. The median follow-up for the two surviving 
patients is 17.9 months (range, 4.1–31.7). The median number 
of treatment cycles delivered was 2 (range, 1–18). 39 patients 
(75%) discontinued treatment because of disease progression, 
six patients (12%) died on study because of their disease, five 
patients (10%) refused further treatment, one patient (2%) 
changed to alternate-treatment, and one patient (2%) discon-
tinued because of adverse events.
All 52 evaluable patients were assessed for adverse events 
according to the common terminology criteria for adverse 
events version 3.0. Grade 3+ adverse events were reported in 
33 patients (64%). Grade 4+ adverse events were reported in 
12 patients (23%). The most common (occurring in three or 
more patients) grade 3/4 events were dyspnea (12%), fatigue 
(10%), hyperglycemia (8%), hypoxia (8%), nausea (8%), and 
rash/desquamation (6%). There were no toxic deaths.
At stage I, two confirmed PRs were observed and thus 
per design, the study reopened for stage II accrual. Among 
all 52 evaluable patients, the clinical benefit rate was 35% 
(18/52). Four patients (8%, 95% confidence interval (CI); 
2–19%) achieved a confirmed PR (Fig. 1) and 14 patients 
(27%, 95% CI; 16%–41%) had confirmed SD. The 24-week 
PFS rate was 25% (13/52: 95% CI: 14%–39%). The median 
PFS and oS were 2.3 (95% CI: 1.8–3.7) and 6.6 (95% CI: 
3.5–10.4) months, respectively (Fig. 2).
In order to identify possible temsirolimus predictive 
markers, we assessed Akt, phosphorylated Akt, p70s6 kinase, 
phosphorylated p70s6 kinase, and PTEN in pretreatment 
tumor specimens (Fig. 3). There was no statistically significant 
TABLE 1. Baseline Patient Characteristics
Characteristics N (%)
Median age (range) 64 (44–85)
Gender
 Female 20 (38.5)
 Male 32 (61.5)
Race
 White 49 (94.2)
 Asian 2 (3.9)
 Native Hawaiian or other Pacific Islander 1 (1.9)
Performance score
 0 25 (48.1)
 1 23 (44.2)
 2 4 (7.7)
Staging
 T4 (pleural effusion) 8 (15.4)
 IV 44 (84.6)
Hepatic metastases
 Yes 10 (19.2)
 No 42 (80.8)
Status of primary tumor
 Recurrence 4 (7.7)
 Newly diagnosed 48 (92.3)
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relationship between any of biomarkers and the response of 
treatment (Table 2). No PTEN mutations were detected in our 
population.
DISCUSSION
The effect of single targeted agent therapy in second-
line NSCLC is modest, with response rates around 10%, 
median PFS around 3 months and median survival around 7 to 
8 months.11,12 It had been hypothesized that prior chemother-
apy might confer resistance in the tumors, which precluded 
the evaluation of the true activity of novel agents.
To address this question, the window of opportunity 
design has been suggested. There are ethical concerns with 
this approach of using a new agent with unknown efficacy 
upfront, when standard treatment is available. We demon-
strated in this study that this approach is feasible and ethi-
cal when the study is carefully designed to closely monitor 
patients and administer standard therapy at the initial sign of 
disease progression, but this approach is not recommended in 
the unselected population.
In this study, temsirolimus as a single agent in frontline 
NSCLC, achieved a clinical benefit rate of 35% (8% confirmed 
PR and 27% with stable disease) in 52 patients. The median 
PFS was 2.3 months and the oS was 6.6 months, with accept-
able toxicity. Although these results did not meet the protocol- 
defined criteria for success, they did document clinical activity 
of temsirolimus as a single agent in NSCLC. our previous phase 
I study of temsirolimus in solid tumors demonstrated a confirmed 
PR in previously treated NSCLC lasting for 12.7 months.13 The 
phase II study of everolimus in second-line NSCLC achieved a 
median PFS of 2.6 months, a 4.8 % of overall response rate, and 
an overall disease control rate of 47.1%.14
In spite of this early hint of activity, subsequent studies 
of mToR inhibitors as single agents (including the present 
FIGURE 1. Computed tomography chest 
showed partial response during the treatment of 
one of the participating patients.
FIGURE 2. Kaplan-Meier survival curve. CI, confidence 
interval.
FIGURE 3. Immunohistochemistry staining of 
p70s6kinase phosphorylation in pretreatment 
tumor samples.
922 Copyright © 2012 by the International Association for the Study of Lung Cancer
Reungwetwattana et al. Journal of Thoracic Oncology  •  Volume  7, Number 5, May 2012
study) have yielded disappointing results. In recent years, pre-
clinical data have demonstrated that treatment of cell lines with 
mToR inhibitors lead to the downregulation of p70s6K and 
phospho 4E binding protein-1 but paradoxically can lead to 
an upregulation of Akt phosphorylation.5 This is likely caused 
by an inhibition of a normally occurring negative-feedback 
loop. An increase in Akt phosphorylation is likely to promote 
tumor survival and clearly limits the potential clinical efficacy 
of single-agent mToR inhibitors.
Predictive biomarkers are needed in order to success-
fully incorporate the mToR inhibitors into lung cancer therapy. 
Forgacs et al. found PTEN/MMAC1 gene mutations in three 
of 18 NSCLC cell lines.15 A study done by the neuro-oncology 
group of North Central Cancer Treatment Group in recurrent 
glioblastoma multiforme patients found significant correla-
tion (p = 0.04) between radiographic improvement after the 
treatment with temsirolimus and high levels of p70s6 kinase 
phosphorylation in baseline tumor tissue.8 We could not find 
any associations of p70s6 kinase, phospho-p70s6 kinase, AKT, 
phospho-AKT expression, and the mutation of PTEN with the 
clinical outcome in this study. However, the small sample size 
precluded any conclusions been drawn (only 4 patients with 
PR were included in the response to treatment group). These 
biomarkers need to be evaluated in future studies.
In conclusion, this study failed to meet its efficacy end-
point, the window of opportunity design was feasible and 
helpful in documenting the clinical activity of temsirolimus in 
NSCLC. NSCLC development is a multistep process linked to 
several intracellular pathways and several genetic alterations. 
Thus, the use of single targeted agent in unselected population 
may not be the optimal strategy.
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TABLE 2. The Correlation of Akt, Phospho-Akt, p70s6k, and 
Phospho-p70s6k by Immunohistochemistry Staining Index 






Treatment (%) p Value
Akt ≥ 200 58 71 0.39
P-Akt ≥ 200 58 35 0.15
p70s6k ≥ 200 77 76 1.00
P-p70s6k ≥ 200 78 71 0.48
